Klotho Neurosciences to Host Inaugural Conference on Klotho-Based Therapies & Diagnostics

Klotho Neurosciences, a biotech company developing therapies for neurodegenerative diseases based on Klotho, announced that CEO Dr. Joseph Sinkule will attend the inaugural Klotho Conference & Scientific Seminar. The event, featuring research on Klotho-based therapies and diagnostics for ALS, Alzheimer's, and longevity, will take place at the UC-Irvine Beal Applied Innovation Center from September 15-16, 2025. Dr. Sinkule will be available to meet with investors and potential partners. Interested parties can contact [email protected].

Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biotechnology company focused on developing Klotho-based therapeutics for neurodegenerative diseases, has announced that CEO and Chairman Dr. Joseph Sinkule will attend the Inaugural Klotho Conference & Scientific Seminar. The event, the first of its kind, will be held at the UC-Irvine Beal Applied Innovation Center in Irvine, California, from September 15-16, 2025 [1].

The conference will feature presentations by the company's key scientific advisors and inventors, Dr. Miguel Chillon and Dr. Assumpcio Bosch. Their research will focus on Klotho gene therapy for treating ALS, Alzheimer's disease, and longevity. Dr. Sinkule will be available to meet with investors and potential partners during the conference. Interested parties can contact [email protected] for more information [2].

Klotho Neurosciences is dedicated to developing innovative, disease-modifying cell and gene therapies using a protein derived from the "anti-aging" human Klotho gene (s-KL). The company's portfolio includes proprietary cell and gene therapy programs and genomics-based diagnostic assays, aimed at transforming the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease, and Parkinson's disease [1].

The company's forward-looking statements, which include descriptions of future commercial operations, are subject to risks and uncertainties. These include the company's ability to implement its business plans, identify and realize additional opportunities, and meet or exceed its financial projections, as well as changes in the regulatory or competitive environment [1].

References:
[1] https://www.prnewswire.com/news-releases/klotho-neurosciences-ceo-to-attend-inaugural-conference--scientific-seminar-302548238.html
[2] https://www.stocktitan.net/news/KLTO/klotho-neurosciences-ceo-to-attend-inaugural-conference-scientific-4lbht6bpw3v1.html